Quest Diagnostics Inc. logo

Quest Diagnostics Inc. (DGX)

Market Closed
3 Jun, 20:00
NYSE NYSE
$
193. 67
+0.51
+0.26%
$
21.72B Market Cap
20.12 P/E Ratio
5.98% Div Yield
416,318 Volume
8.71 Eps
$ 193.16
Previous Close
Add Transaction
Day Range
192.38 195.21
Year Range
164.65 213.5
Want to track DGX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Here's How Quest Diagnostics Is Placed Ahead of Q1 Earnings

Here's How Quest Diagnostics Is Placed Ahead of Q1 Earnings

DGX heads into Q1 earnings with steady growth expectations, but estimate cuts and a negative ESP could temper the outlook.

Zacks | 1 month ago
Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth

Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 month ago
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 2 months ago
Quest Diagnostics Incorporated $DGX Stock Position Increased by 8 Knots Management LLC

Quest Diagnostics Incorporated $DGX Stock Position Increased by 8 Knots Management LLC

8 Knots Management LLC grew its position in Quest Diagnostics Incorporated (NYSE: DGX) by 56.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 275,344 shares of the medical research company's stock after purchasing an additional 98,806 shares during the period. Quest Diagnostics makes

Defenseworld | 2 months ago
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term

Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 2 months ago
Quest Diagnostics (DGX) Down 4.2% Since Last Earnings Report: Can It Rebound?

Quest Diagnostics (DGX) Down 4.2% Since Last Earnings Report: Can It Rebound?

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?

Zacks | 2 months ago
Quest Diagnostics Incorporated (DGX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Quest Diagnostics Incorporated (DGX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Quest Diagnostics Incorporated (DGX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Seekingalpha | 2 months ago
Should You Continue to Hold DGX Stock in Your Portfolio?

Should You Continue to Hold DGX Stock in Your Portfolio?

Quest Diagnostics posts strong gains from physician and hospital channels while advancing AI-powered solutions.

Zacks | 2 months ago
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term

Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 3 months ago
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 3 months ago
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?

Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks | 3 months ago
Quest Diagnostics' Q4 Earnings & Revenues Beat Estimates, Stock Up

Quest Diagnostics' Q4 Earnings & Revenues Beat Estimates, Stock Up

DGX tops Q4 EPS and revenue estimates as volumes rise, shares jump premarket, and 2026 guidance points to steady growth.

Zacks | 3 months ago
Loading...
Load More